IMMUNITYBIO, INC. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
IMMUNITYBIO, INC. (IBRX) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $1.05 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-02-23
- IMMUNITYBIO, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $1.05M, a 16.23% decline from fiscal 2024.
- IMMUNITYBIO, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $1.25M, a 93.41% decline from fiscal 2023.
- IMMUNITYBIO, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $18.98M, a 1009.71% increase from fiscal 2022.
- IMMUNITYBIO, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $1.71M, a 219.03% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $1.05M 10-K · filed 2026-02-23 |
| 2024-12-31 | $1.25M 10-K · filed 2026-02-23 |
| 2023-12-31 | $18.98M 10-K · filed 2026-02-23 |
| 2022-12-31 | $1.71M 10-K · filed 2025-03-03 |
| 2021-12-31 | $536.00K 10-K · filed 2024-03-19 |
| 2020-12-31 | $4.76M 10-K · filed 2023-03-01 |
| 2019-12-31 | $3.68M 10-K · filed 2022-03-01 |
| 2018-12-31 | $4.61M 10-K · filed 2020-03-25 |
| 2017-12-31 | $2.75M 10-K · filed 2019-03-13 |
| 2016-12-31 | $2.06M 10-K · filed 2018-03-12 |
| 2015-12-31 | $1.08M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |